In China, vaccine is customarily divided into vaccine I and Vaccine II. Vaccine I is offered for free, and it's priced and purchased uniformly by government, covering the major epidemic diseases of Hepatitis B, Idemic Encephalitis, Tetanus, etc. Vaccine II is that vaccine which is inoculated voluntarily at people's own expense. It is independently priced and has large profit margins, but there are intense competitions in the market. The frequently-used Vaccine II includes Pneumonia vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine, Rabies Vaccine and so on. In China, Vaccine I markets are occupied by state-owned enterprises, while foreign-funded enterprises and private enterprises have certain advantages in Vaccine II markets.
Request a Sample for or Inquire before buying the report@
Major points covered in Table of Contents of this report include:
General Introduction of Human Vaccine Industry
Analysis on the Global Vaccine Market
Analysis on Policy of Chinese Vaccine Industry
Analysis on Chinese Vaccine Market
Analysis on Chinese Vaccine Market
China's Major Vaccine Manufacturers
Prediction on Development of Chinese Vaccine Industry
Because of the low per capital income and the lack of medical guarantee, the market scale of Chinese Vaccine is relatively small. However, driven by many factors, it has good market prospects.
Request a Sample for or Inquire before buying the report@
The great demands of Chinese vaccine market attract many leading enterprises of international vaccine industry to invest. In 2008, Sanofi Pasteur invested USD 94 million to build vaccine factories. In 2009, Novartis bought 85% of shareholding of Zhejiang Tianhua Co., Ltd. at the cost of USD 125 million and was registered in March 2011. In May 2011, GSK ended the cooperation with Watson Biological Company, and in June, it bought 51% shareholding of Haiwang Yingtelong Biotechnology Co., Ltd. at the cost of GBP 24 million and established wholly-owned subsidiary company. In September 2011, GlaxoSmithKline signed contracts with Sinopharm, Shanghai Zuellig Pharmaceutical Co., Ltd. and Beijing Keyuan Pharmaceutical Co., Ltd. The three distributors are responsible for the business of the North China, the central parts and the South China respectively and provide services for customers through the cold chain logistics system covering all over the country.
In the next few years, it's expected, Chinese vaccine market will maintain a rapid growth, but the competition will be fiercer. Parts of less competitive enterprises will go bankrupt or be merged and reorganized, and the concentration rate of vaccine market will keep an increase.
Major points covered in Table of Contents of this report include:
General Introduction of Human Vaccine Industry
Analysis on the Global Vaccine Market
Analysis on Policy of Chinese Vaccine Industry
Analysis on Chinese Vaccine Market
Analysis on Chinese Vaccine Market
China's Major Vaccine Manufacturers
Prediction on Development of Chinese Vaccine Industry
See More
Published: March 2012
No.of Pages:
Price: Single User License - US $ 3000
Healthcare Market Research Reports
Report Details :Published: March 2012
No.of Pages:
Price: Single User License - US $ 3000
Corporate User License- 4500
Post a Comment